tiprankstipranks
AbbVie price target raised to $200 from $195 at UBS
The Fly

AbbVie price target raised to $200 from $195 at UBS

UBS raised the firm’s price target on AbbVie (ABBV) to $200 from $195 and keeps a Neutral rating on the shares. AbbVie reported another impressive quarter and the focus now turns to emraclidine and 2025, the analyst tells investors in a research note.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App